LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and ...

Eli Lilly ( LLY) is expected to see a multi-fold increase in its earnings during its third quarter earnings, which is scheduled for October 29 after markets close. The pharma giant is expected to ...

The site will also help make treatments for heart disease, diabetes, cancer, and autoimmune disorders areas where Lilly has ...

The idea was beautifully simple. One pill taken daily to melt away those excess pounds. The new breed of GLP-1 oral ...

The drugmaker Eli Lilly reports its third-quarter results early Thursday, as questions loom about what kind of deal it will reach with the Trump administration over the price of its weight-loss drug.

A MAJOR review has pitted three blockbuster fat jabs against each other – comparing weight lost and how long users were able ...

Until recently, GLP-1s, a powerful new class of weight-loss drugs, were confined mostly to rich countries. Yet the World Obesity Federation, a charity, reckons that two-thirds of the world’s 1bn obese ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

The Indianapolis-based Eli Lilly and Co. said the improved facility in Carolina, Puerto Rico, will make orforglipron, Lilly’s highly anticipated GLP-1 pill.

Lilly partners with Walmart to offer weight-loss drug Zepbound at nationwide pharmacies, expanding access to the medication.

Scientific research has found the surprising effect taking weight loss drugs while smoking and vaping could have on your body ...